Aurora Cannabis Inc. (ACB)
USD 4.84
(1.89%)
USD 4.84
(1.89%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 158.53 Million CAD | -16.54% |
| 2022 | 189.95 Million CAD | -21.05% |
| 2021 | 240.6 Million CAD | 6.89% |
| 2020 | 225.08 Million CAD | -50.08% |
| 2019 | 450.93 Million CAD | -1.29% |
| 2018 | 456.84 Million CAD | 269.53% |
| 2017 | 123.62 Million CAD | 381.1% |
| 2016 | 25.69 Million CAD | 278.29% |
| 2015 | 6.79 Million CAD | 55.55% |
| 2014 | 4.36 Million CAD | 1324.92% |
| 2013 | 306.48 Thousand CAD | -23.93% |
| 2012 | 402.87 Thousand CAD | 21.79% |
| 2011 | 330.78 Thousand CAD | 64.3% |
| 2010 | 201.33 Thousand CAD | 248.53% |
| 2009 | 57.76 Thousand CAD | -68.97% |
| 2008 | 186.18 Thousand CAD | -18.71% |
| 2007 | 229.04 Thousand CAD | 18282.58% |
| 2006 | 1246.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 32.38 Million CAD | -52.93% |
| 2023 Q2 | 42.12 Million CAD | 30.07% |
| 2023 Q3 | 43.74 Million CAD | 3.85% |
| 2023 FY | 158.53 Million CAD | -16.54% |
| 2022 Q3 | 41.26 Million CAD | -21.24% |
| 2022 Q4 | 68.8 Million CAD | 66.74% |
| 2022 Q2 | 52.39 Million CAD | 4.37% |
| 2022 Q1 | 50.2 Million CAD | -27.04% |
| 2022 FY | 189.95 Million CAD | -21.05% |
| 2021 Q4 | 68.8 Million CAD | 20.37% |
| 2021 Q1 | 50.23 Million CAD | -18.61% |
| 2021 FY | 240.6 Million CAD | 6.89% |
| 2021 Q2 | 64.39 Million CAD | 28.18% |
| 2021 Q3 | 57.16 Million CAD | -11.23% |
| 2020 Q4 | 61.72 Million CAD | 16.89% |
| 2020 Q1 | 67.84 Million CAD | 6.6% |
| 2020 Q2 | 42.71 Million CAD | -37.03% |
| 2020 FY | 225.08 Million CAD | -50.08% |
| 2020 Q3 | 52.8 Million CAD | 23.61% |
| 2019 Q3 | 109.67 Million CAD | -25.63% |
| 2019 Q4 | 63.64 Million CAD | -41.97% |
| 2019 Q2 | 147.46 Million CAD | 13.31% |
| 2019 Q1 | 130.14 Million CAD | 11.04% |
| 2019 FY | 450.93 Million CAD | -1.29% |
| 2018 Q4 | 117.2 Million CAD | -8.48% |
| 2018 FY | 456.84 Million CAD | 269.53% |
| 2018 Q1 | 104.94 Million CAD | 73.97% |
| 2018 Q2 | 106.64 Million CAD | 1.62% |
| 2018 Q3 | 128.05 Million CAD | 20.08% |
| 2017 Q1 | 9.88 Million CAD | 23.54% |
| 2017 Q4 | 60.32 Million CAD | 84.9% |
| 2017 FY | 123.62 Million CAD | 381.1% |
| 2017 Q3 | 32.62 Million CAD | 56.91% |
| 2017 Q2 | 20.79 Million CAD | 110.28% |
| 2016 Q3 | 7.59 Million CAD | 12.75% |
| 2016 Q2 | 6.73 Million CAD | 100.44% |
| 2016 FY | 25.69 Million CAD | 278.29% |
| 2016 Q4 | 8 Million CAD | 5.37% |
| 2016 Q1 | 3.36 Million CAD | 32.24% |
| 2015 FY | 6.79 Million CAD | 55.55% |
| 2015 Q4 | 2.54 Million CAD | 66.91% |
| 2015 Q3 | 1.52 Million CAD | -1.51% |
| 2015 Q2 | 1.54 Million CAD | 30.76% |
| 2015 Q1 | 1.18 Million CAD | 429.77% |
| 2014 Q2 | 1.18 Million CAD | 118.47% |
| 2014 Q1 | 542.73 Thousand CAD | 288.14% |
| 2014 Q4 | -358.55 Thousand CAD | -152.01% |
| 2014 FY | 4.36 Million CAD | 1324.92% |
| 2014 Q3 | 689.46 Thousand CAD | -41.85% |
| 2013 FY | 306.48 Thousand CAD | -23.93% |
| 2013 Q4 | 139.82 Thousand CAD | 47.9% |
| 2013 Q3 | 94.54 Thousand CAD | 207.19% |
| 2013 Q1 | 41.34 Thousand CAD | -61.45% |
| 2013 Q2 | 30.77 Thousand CAD | -25.56% |
| 2012 Q3 | 75.2 Thousand CAD | 6.71% |
| 2012 FY | 402.87 Thousand CAD | 21.79% |
| 2012 Q1 | 151.76 Thousand CAD | -24.9% |
| 2012 Q2 | 70.47 Thousand CAD | -53.56% |
| 2012 Q4 | 107.24 Thousand CAD | 42.6% |
| 2011 FY | 330.78 Thousand CAD | 64.3% |
| 2011 Q3 | 45.31 Thousand CAD | 16.59% |
| 2011 Q1 | 44.52 Thousand CAD | -59.71% |
| 2011 Q2 | 38.86 Thousand CAD | -12.71% |
| 2011 Q4 | 202.08 Thousand CAD | 346.0% |
| 2010 Q1 | 37.74 Thousand CAD | 54.79% |
| 2010 FY | 201.33 Thousand CAD | 248.53% |
| 2010 Q4 | 110.51 Thousand CAD | 166.96% |
| 2010 Q3 | 41.39 Thousand CAD | -13.35% |
| 2010 Q2 | 47.77 Thousand CAD | 26.57% |
| 2009 Q2 | 13.3 Thousand CAD | -46.71% |
| 2009 Q1 | 24.95 Thousand CAD | 0.94% |
| 2009 Q3 | 15.68 Thousand CAD | 17.9% |
| 2009 Q4 | 24.38 Thousand CAD | 55.51% |
| 2009 FY | 57.76 Thousand CAD | -68.97% |
| 2008 Q1 | 92.36 Thousand CAD | 128.63% |
| 2008 Q2 | 32.4 Thousand CAD | -64.92% |
| 2008 Q4 | 24.72 Thousand CAD | -32.62% |
| 2008 FY | 186.18 Thousand CAD | -18.71% |
| 2008 Q3 | 36.69 Thousand CAD | 13.25% |
| 2007 Q3 | 22.26 Thousand CAD | -86.5% |
| 2007 Q4 | 40.39 Thousand CAD | 81.46% |
| 2007 Q2 | 164.96 Thousand CAD | 11476.14% |
| 2007 Q1 | 1425.00 CAD | 0.0% |
| 2007 FY | 229.04 Thousand CAD | 18282.58% |
| 2006 FY | 1246.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 271.89 Million USD | 41.692% |
| Theratechnologies Inc. | 72.75 Million USD | -117.905% |
| Safety Shot Inc | 12.1 Million USD | -1209.191% |
| Cosmos Health Inc. | 26.18 Million USD | -505.555% |
| Cronos Group Inc. | 96.7 Million USD | -63.934% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 31.701% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -304.922% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 49.531% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1045.355% |
| ProPhase Labs, Inc. | 37.85 Million USD | -318.839% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1578.372% |
| Dynavax Technologies Corporation | 219.14 Million USD | 27.656% |
| Radius Health, Inc. | 265.92 Million USD | 40.383% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -5065.503% |
| Alvotech | 285.43 Million USD | 44.458% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1107.965% |
| Alpha Teknova, Inc. | 45.85 Million USD | -245.71% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 73.129% |
| SCYNEXIS, Inc. | 51.84 Million USD | -205.777% |
| Harrow Health, Inc. | 89.97 Million USD | -76.207% |
| Biofrontera Inc. | 39.95 Million USD | -296.754% |
| DURECT Corporation | 43.71 Million USD | -262.665% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 70.031% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 19.106% |
| OptiNose, Inc. | 85.1 Million USD | -86.293% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1758.184% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -253.456% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -268.348% |
| SIGA Technologies, Inc. | 22.04 Million USD | -619.225% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -223.298% |
| Shineco, Inc. | 17.94 Million USD | -783.322% |
| Phibro Animal Health Corporation | 260.29 Million USD | 39.093% |
| Procaps Group S.A. | 187.24 Million USD | 15.331% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1513.628% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -3872.276% |
| Viatris Inc. | 5.96 Billion USD | 97.343% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1107.965% |
| Rockwell Medical, Inc. | 15.37 Million USD | -931.215% |
| Incannex Healthcare Limited | 30.05 Million USD | -427.531% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -164.938% |
| Tilray Brands, Inc. | 251.35 Million USD | 36.927% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 0.42% |
| PetIQ, Inc. | 192.72 Million USD | 17.738% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -20692.218% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 90.07% |
| Journey Medical Corporation | 54.59 Million USD | -190.396% |
| Alimera Sciences, Inc. | 62.64 Million USD | -153.091% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -790.242% |
| Assertio Holdings, Inc. | 368.58 Million USD | 56.987% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2593.689% |
| Embecta Corp. | 528.4 Million USD | 69.996% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -653.437% |
| Procaps Group, S.A. | 199.47 Million USD | 20.523% |
| PainReform Ltd. | 9.58 Million USD | -1554.205% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 3.896% |
| Hempacco Co., Inc. | 7.59 Million USD | -1987.015% |
| Talphera, Inc. | 11.99 Million USD | -1221.819% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 51.425% |
| Alvotech | 285.43 Million USD | 44.458% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 54.033% |
| Kamada Ltd. | 45.42 Million USD | -249.005% |
| Indivior PLC | 911 Million USD | 82.597% |
| Currenc Group, Inc. | 24 Million USD | -560.522% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1177.547% |
| Flora Growth Corp. | 10.57 Million USD | -1398.62% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -653.437% |
| Evolus, Inc. | 189.75 Million USD | 16.452% |
| HUTCHMED (China) Limited | 436.23 Million USD | 63.657% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -2.858% |
| Akanda Corp. | 3.48 Million USD | -4451.131% |